A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury

Trial Profile

A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs OPC 1 (Primary)
  • Indications Spinal cord injuries
  • Focus Adverse reactions; Proof of concept
  • Acronyms SCi-STAR; SCiSTAR
  • Sponsors Asterias Biotherapeutics
  • Most Recent Events

    • 09 Aug 2017 According to an Asterias Biotherapeutics media release, company plans to increase trial sites from 8 to 12.
    • 09 Aug 2017 According to an Asterias Biotherapeutics media release, enrollment for entire trial is expected to complete by the end of 2017, and multiple safety and efficacy readouts are expected during the remainder of 2017 and 2018.
    • 09 Aug 2017 According to an Asterias Biotherapeutics media release, first patient in the fifth and final cohort of this trial has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top